Merck cans one COVID-19 drug, scraps a clinical trial of another

Merck has disclosed more setbacks to its COVID-19 strategy. Having already pulled out of vaccines, Merck has now stopped developing one medicine in hospitalized patients and given up completely on another drug in COVID-19.